Trial Search Results

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Santhera Pharmaceuticals

Stanford Investigator(s):

Intervention(s):

  • Drug: Idebenone 150 MG Oral Tablet

Eligibility


Inclusion Criteria:

   - Patients who completed the LEROS study, who attended the end of study visit in LEROS
   and who in the opinion of investigator could benefit from continuation of idebenone
   treatment.

   - Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from
   patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the
   patient).

Exclusion Criteria:

   - Patients who, in the opinion of the LEROS investigator, had unacceptable tolerability
   of idebenone treatment in LEROS trial.

   - Patients who prematurely discontinued the LEROS study.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305